The first-in-class anti-axlcd3 pronectin™-based bispecific t-cell engager is active in preclinical models of human soft tissue and bone sarcomas

HIGHLIGHTS

• who: Nicoletta Poleru00e0 et al. from the Department of Experimental and Clinical Medicine, Magna Gru00e6cia University, Catanzaro, Italy have published the article: The First-In-Class Anti-AXLCD3 Pronectinu2122-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas, in the Journal: Cancers 2023, 1647 of 10/02/2023
• what: On these premises, the authors focused on AXL as an immunotherapeutic target to be exploited in sarcoma treatment by BTCE-based strategy. The authors demonstrate that the first-in-class pAXLu00d7CD3u03b5-based immunotherapy exerts significant anti-sarcoma activity . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.